{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Klotho Neurosciences, Inc."},"Symbol":{"label":"Symbol","value":"KLTOW"},"Address":{"label":"Address","value":"13576 WALNUT STREET,SUITE A SUITE A, OMAHA, Nebraska, 68144, United States"},"Phone":{"label":"Phone","value":"(833) 931-6330"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Klotho Neurosciences, Inc. (NASDAQ: KLTO), a biopharmaceutical company specializing in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders. The Company obtained exclusive worldwide rights to platform technologies and knowhow to develop cutting edge protein, gene and cell therapies to treat age-related pathologies such as ALS, Alzheimer's and Parkinson's Disease, multiple sclerosis and rare neurodegenerative diseases. The company's current portfolio consists of its proprietary gene therapy program using DNA and RNA as therapeutics and diagnostics. Other assets include clinical-stage programs involving antibody biologics targeting cancer and autoimmune diseases, and drug delivery via a needle-free dry powder jet autoinjector called Nanoject."},"CompanyUrl":{"label":"Company Url","value":"www.klothoneuro.com"},"KeyExecutives":{"label":"Key Executives","value":[]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}